Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 August 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

NIH consensus on antiviral therapy for adults with chronic Hep B

This month’s Annals of Internal Medicine reports on the National Institutes of Health Consensus Development Conference on antiviral therapy for chronic Hep B.

News image

fiogf49gjkf04

Chronic Hepatitis B infection can lead to liver failure, hepatocellular carcinoma, and death.

Dr Tatyana Shamliyan and colleagues evaluated the effectiveness of antiviral therapy for adults with chronic Hepatitis B infection.

The team identified randomized, controlled trials of interferon, lamivudine, adefovir, entecavir, and telbivudine published from 1990 to 2008.

In addition, randomized, controlled clinical trials of adults with chronic Hepatitis B published in English after 1989 that reported death were assessed.

The team recorded the incidence of hepatocellular carcinoma or liver failure, prevalence and incidence of cirrhosis.

The presence or seroconversion of Hepatitis B e antigen or surface antigen, viral load of Hepatitis B virus DNA was also recorded.

Drug treatment did not improve clinical outcomes of chronic Hep B
Annals of Internal Medicine

The team measured aspartate aminotransferase and alanine aminotransferase levels.

Fibrosis scores after therapy with interferon-2b, pegylated interferon-2a, lamivudine, adefovir, entecavir, and telbivudine was assessed.

The team extracted data with standard protocols to calculate risk difference for clinical outcomes, viral load, Hepatitis B e antigen or surface antigen, alanine aminotransferase levels, histologic scores, and adverse events.

In 16 randomized controlled trials including 4431 patients, drug treatment did not improve clinical outcomes of chronic Hepatitis B infection.

However, the team reported that the trials were underpowered.

In 60 randomized controlled trials that examined intermediate outcomes, the team found no single treatment improved all intermediate outcomes.

Low-quality evidence suggested Hepatitis B e surface antigen clearance after interferon-2b, including 2 randomized controlled trials of 211 patients.

The team found that moderate-quality evidence suggested alanine aminotransferase levels normalization at follow-up after treatment with adefovir, and Hepatitis B e antigen loss with lamivudine.

With interferon-2b, moderate-quality evidence suggested Hepatitis B e antigen loss, seroconversion, and alanine aminotransferase levels normalization.

Pegylated interferon-2a versus lamivudine improved Hepatitis B e antigen seroconversion, and alanine aminotransferase levels normalization off treatment.

The team observed that pegylated interferon-2a combined with lamivudine versus lamivudine improved Hepatitis B e antigen loss, and alanine aminotransferase levels normalization.

Adverse events during antiretroviral therapy occurred in more than 50% of patients, but were not associated with increased treatment discontinuation.

However, the research team noted that most studies excluded patients with hepatic or renal insufficiency or other serious comorbid conditions.

Dr Shamliyan’s team concludes, “Evidence was insufficient to assess treatment effect on clinical outcomes or determine whether inconsistent improvements in selected intermediate measures are reliable surrogates.”

“Future research is needed to provide evidence-based recommendations about optimal antiviral therapy in adults with chronic Hepatitis B infection.”  

Ann Int Med 2009: 150(2)


08 January 2009

Go to top of page Email this page Email this page to a colleague

 23 August 2017 
Outcomes of bowel cancer screening with a fecal immunochemical test
 23 August 2017 
Arterial stiffness in NAFLD
 23 August 2017 
Colectomy rates in patients with ulcerative colitis
 22 August 2017 
Improving the diagnostic accuracy of severe liver fibrosis in NAFLD
 22 August 2017 
New therapies to manage Hep B
 22 August 2017 
Survival in patients with Lynch syndrome
 21 August 2017 
Improving medication adherence in IBD
 21 August 2017 
Treatments for chronic idiopathic constipation
 21 August 2017 
Ethnic disparities for chronic Hep C survival
 18 August 2017 
Proteomic analysis of IBD
 18 August 2017 
Pediatric intestinal failure
 18 August 2017 
Anti-TNF treatment and bowel resection in Crohn's
 17 August 2017 
Outcomes of ulcerative colitis patients undergoing pouch surgery
 17 August 2017 
Mortality in patients with asymptomatic pancreatic cystic neoplasms
 17 August 2017 
Survival after primary tumor resection in advanced colorectal cancer
 16 August 2017 
Assessment of seronegative villous atrophy
 16 August 2017 
Appendectomy and colectomy risk in ulcerative colitis
 16 August 2017 
Gluten sensitivity and celiac disease
 15 August 2017 
Infliximab and treatment failure during maintenance
 15 August 2017 
Genetic in idiopathic pancreatitis
 15 August 2017 
Genetic factors and tobacco in IBD
 14 August 2017 
Per oral endoscopic myotomy
 14 August 2017 
Early colonoscopy and symptomatic colorectal cancer
 14 August 2017 
Ethnic disparities and Hep C survival
 11 August 2017 
Ledipasvir and sofosbuvir in treatment-naïve Hep C
 11 August 2017 
EBV DNA to screen for nasopharyngeal cancer
 11 August 2017 
Direct acting antivirals and mixed cryoglobulinemia
 10 August 2017 
Routine preoperative laboratory tests for elective surgery
 10 August 2017 

Whole-genome sequencing in primary care

 10 August 2017 
Mortality in cirrhosis
 09 August 2017 
Anticoagulants in cirrhosis
 09 August 2017 
Low birthweight and pediatric NAFLD
 09 August 2017 
IBS with extraintestinal somatic and psychological symptoms
 08 August 2017 
Prior Barrett’s diagnosis and esophageal cancer survival
 08 August 2017 
Imaging index for fistulizing Crohn's
 08 August 2017 
Statin use after colon cancer
 07 August 2017 
Contraindications of biologic therapies in IBD
 07 August 2017 
Predicting clinical outcome in colorectal cancer
 07 August 2017 
Future burden of esophageal cancer
 04 August 2017 
Internet decision-making resources for ulcerative colitis surgery
 04 August 2017 
Distal findings and proximal colorectal neoplasia
 04 August 2017 
CT colonography vs flexible sigmoidoscopy
 03 August 2017 
Bloating and abdominal distension
 03 August 2017 
Predictors of colectomy in ulcerative colitis
 03 August 2017 
Treatment for sensitized transplant patients
 02 August 2017 
Preventing reactivation of Hep B
 02 August 2017 
Improving medication adherence in IBD
 02 August 2017 
Multiply recurrent C. difficile in the USA
 01 August 2017 
Coping with IBD
 01 August 2017 
Hepatocellular carcinoma in autoimmune hepatitis
 01 August 2017 
Anti-TNF treatment in Crohn's disease
 31 July 2017 
Global HCV incidence and mortality elimination targets
 31 July 2017 
Diagnosing GERD
 31 July 2017 
Diagnostic accuracy of severe liver fibrosis in patients with NAFLD
 28 July 2017 
Low FODMAP diet in IBS
 28 July 2017 
IBD patient–centered medical home
 28 July 2017 
Excluding NAFLD in the general population
 27 July 2017 
H. pylori infection and preeclampsia
 27 July 2017 
Colorectal cancer increases in developed and developing regions
 27 July 2017 
Anger in HIV-HCV co-infected patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us